Deep Track Capital’s Protagonist Therapeutics PTGX Stock Holding History

Deep Track Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,715,691	Closed	-$114M	–	69
2025 Q3	$114M	Sell	1,715,691 -1,530,208	-47%	-$87M	3.18%	13
2025 Q2	$179M	Buy	3,245,899 +245,899	+8%	+$11.8M	5.75%	3
2025 Q1	$145M	Buy	3,000,000 +2,000,000	+200%	+$83.8M	4.7%	5
2024 Q4	$38.6M	Buy	+1,000,000	New	+$43.6M	1.44%	24
2024 Q1	–	Sell	-275,201	Closed	-$6.31M	–	76
2023 Q4	$6.31M	Buy	+275,201	New	+$4.82M	0.21%	56
2023 Q1	–	Sell	-871,493	Closed	-$9.51M	–	69
2022 Q4	$9.51M	Buy	+871,493	New	+$7.35M	0.4%	46
2022 Q1	–	Sell	-421,660	Closed	-$11.9M	–	60
2021 Q4	$14.4M	Buy	+421,660	New	+$13.3M	1.02%	36

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deep Track Capital's PTGX Position: Q4 2025 in Review

Deep Track Capital sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 1,715,691 shares — an estimated $114M sold.

Deep Track Capital first reported a position in PTGX in Q4 2021 and held it in 7 quarters. The position peaked at $179M in Q2 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Deep Track Capital reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Deep Track Capital sold 1,715,691 Protagonist Therapeutics shares in Q4 2025, an estimated $114M.
Deep Track Capital first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 7 quarters.
Deep Track Capital's Protagonist Therapeutics position peaked at $179M in Q2 2025.
313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.